BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 12907616)

  • 21. Oncolytic virotherapy for prostate cancer by E1A, E1B mutant adenovirus.
    Satoh M; Wang H; Ishidoya S; Abe H; Moriya T; Hamada H; Arai Y
    Urology; 2007 Dec; 70(6):1243-8. PubMed ID: 18158069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
    Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
    Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression.
    Kuppuswamy M; Spencer JF; Doronin K; Tollefson AE; Wold WS; Toth K
    Gene Ther; 2005 Nov; 12(22):1608-17. PubMed ID: 16034456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of hepatocellular carcinoma with a novel gene-viral therapeutic system CNHK300-murine endostatin].
    Li GC; Nie MM; Yang JM; Su CQ; Sun LC; Qian YZ; Sham J; Fang GE; Wu MC; Qian QJ
    Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):943-8. PubMed ID: 15329284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Double E1B 19 kDa- and E1B 55 kDa-deleted oncolytic adenovirus in combination with radiotherapy elicits an enhanced anti-tumor effect.
    Kim J; Kim PH; Yoo JY; Yoon AR; Choi HJ; Seong J; Kim IW; Kim JH; Yun CO
    Gene Ther; 2009 Sep; 16(9):1111-21. PubMed ID: 19494843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complete eradication of hepatomas using an oncolytic adenovirus containing AFP promoter controlling E1A and an E1B deletion to drive IL-24 expression.
    Zhang KJ; Zhang J; Wu YM; Qian J; Liu XJ; Yan LC; Zhou XM; Xiao RJ; Wang YG; Cao X; Wei N; Liu XR; Tang B; Jiao XY; Chen K; Liu XY
    Cancer Gene Ther; 2012 Sep; 19(9):619-29. PubMed ID: 22790965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
    Akbulut H; Zhang L; Tang Y; Deisseroth A
    Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel E1A-E1B mutant adenovirus induces glioma regression in vivo.
    Gomez-Manzano C; Balague C; Alemany R; Lemoine MG; Mitlianga P; Jiang H; Khan A; Alonso M; Lang FF; Conrad CA; Liu TJ; Bekele BN; Yung WK; Fueyo J
    Oncogene; 2004 Mar; 23(10):1821-8. PubMed ID: 15014451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene therapy with secretory leukoprotease inhibitor promoter-controlled replication-competent adenovirus for non-small cell lung cancer.
    Maemondo M; Saijo Y; Narumi K; Kikuchi T; Usui K; Tazawa R; Matsumoto K; Nakamura T; Sasaki K; Takahashi M; Niitsu Y; Nukiwa T
    Cancer Res; 2004 Jul; 64(13):4611-20. PubMed ID: 15231673
    [TBL] [Abstract][Full Text] [Related]  

  • 30. E1A- and E1B-Double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects.
    Kim J; Kim JH; Choi KJ; Kim PH; Yun CO
    Hum Gene Ther; 2007 Sep; 18(9):773-86. PubMed ID: 17725410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human papilloma virus E6 and E7 proteins support DNA replication of adenoviruses deleted for the E1A and E1B genes.
    Steinwaerder DS; Carlson CA; Lieber A
    Mol Ther; 2001 Sep; 4(3):211-6. PubMed ID: 11545611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell.
    Tsukuda K; Wiewrodt R; Molnar-Kimber K; Jovanovic VP; Amin KM
    Cancer Res; 2002 Jun; 62(12):3438-47. PubMed ID: 12067986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel tetracycline-controlled transactivator-transrepressor system enables external control of oncolytic adenovirus replication.
    Fechner H; Wang X; Srour M; Siemetzki U; Seltmann H; Sutter AP; ScherĂ¼bl H; Zouboulis CC; Schwaab R; Hillen W; Schultheiss HP; Poller W
    Gene Ther; 2003 Sep; 10(19):1680-90. PubMed ID: 12923567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Arg-Gly-Asp (RGD)-Modified E1A/E1B Double Mutant Adenovirus Enhances Antitumor Activity in Prostate Cancer Cells In Vitro and in Mice.
    Shen YH; Yang F; Wang H; Cai ZJ; Xu YP; Zhao A; Su Y; Zhang G; Zhu SX
    PLoS One; 2016; 11(1):e0147173. PubMed ID: 26799485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model.
    Zhang Y; Yu D; Xia W; Hung MC
    Oncogene; 1995 May; 10(10):1947-54. PubMed ID: 7761095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts.
    Geoerger B; Grill J; Opolon P; Morizet J; Aubert G; Terrier-Lacombe MJ; Bressac De-Paillerets B; Barrois M; Feunteun J; Kirn DH; Vassal G
    Cancer Res; 2002 Feb; 62(3):764-72. PubMed ID: 11830531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ADP-overexpressing adenovirus elicits enhanced cytopathic effect by induction of apoptosis.
    Yun CO; Kim E; Koo T; Kim H; Lee YS; Kim JH
    Cancer Gene Ther; 2005 Jan; 12(1):61-71. PubMed ID: 15375379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy.
    Howe JA; Demers GW; Johnson DE; Neugebauer SE; Perry ST; Vaillancourt MT; Faha B
    Mol Ther; 2000 Nov; 2(5):485-95. PubMed ID: 11082322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. mda-7/IL-24 induces apoptosis in human GBC-SD gallbladder carcinoma cells via mitochondrial apoptotic pathway.
    Jia J; Li S; Gong W; Ding J; Fang C; Quan Z
    Oncol Rep; 2011 Jan; 25(1):195-201. PubMed ID: 21109977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fusion of the BCL9 HD2 domain to E1A increases the cytopathic effect of an oncolytic adenovirus that targets colon cancer cells.
    Fuerer C; Homicsko K; Lukashev AN; Pittet AL; Iggo RD
    BMC Cancer; 2006 Oct; 6():236. PubMed ID: 17020613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.